(IQV) IQVIA Holdings - Ratings and Ratios
Clinical Research, Analytics, Consulting, Outsourcing, Intelligence
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 27.3% |
| Value at Risk 5%th | 41.6% |
| Relative Tail Risk | -7.16% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.41 |
| Alpha | -0.66 |
| CAGR/Max DD | 0.04 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.594 |
| Beta | 0.999 |
| Beta Downside | 1.091 |
| Drawdowns 3y | |
|---|---|
| Max DD | 47.12% |
| Mean DD | 17.14% |
| Median DD | 15.91% |
Description: IQV IQVIA Holdings October 14, 2025
IQVIA Holdings Inc. (NYSE:IQV) delivers an integrated suite of clinical research, commercial insight, and healthcare intelligence services to life-science and health-care firms across the Americas, Europe, Africa, and Asia-Pacific.
The firm operates through three core segments: (1) **Technology & Analytics Solutions**, which provides cloud-based applications, real-world evidence platforms, and advanced-analytics consulting that help clients track prescription trends, sales performance, and promotional activity down to the zip-code and prescriber level; (2) **Research & Development Solutions**, offering end-to-end clinical-trial support, central-lab services, genomics, bioanalysis, and vaccine-biomarker capabilities; and (3) **Contract Sales & Medical Solutions**, focused on provider- and patient-engagement, scientific strategy, and medical-affairs execution for pharma, biotech, device, diagnostic, and consumer-health companies.
IQVIA’s strategic partnership with Sarah Cannon Research Institute enhances its clinical-trial optimization offering, reinforcing the company’s position as a leading outsourced R&D partner.
From a financial-performance perspective, IQVIA reported FY 2023 revenue of roughly **$13.5 billion**, up **~8 % YoY**, driven primarily by double-digit growth in its Technology & Analytics segment (≈12 % YoY) and steady expansion in contract sales services. The company’s operating margin hovered around **13 %**, reflecting the higher-margin nature of its data-analytics and cloud solutions. A key sector driver is the accelerating demand for **real-world evidence (RWE)** and AI-enabled drug-development tools, which the firm is capitalizing on through its expanding cloud platform serving over **2,000** life-science clients.
For deeper quantitative analysis of IQVIA’s valuation metrics, you may find ValueRay’s data platform a useful next step.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (1.28b TTM) > 0 and > 6% of Revenue (6% = 954.2m TTM) |
| FCFTA 0.09 (>2.0%) and ΔFCFTA 1.98pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -15.90% (prev -8.88%; Δ -7.02pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.10 (>3.0%) and CFO 2.80b > Net Income 1.28b (YES >=105%, WARN >=100%) |
| Net Debt (13.38b) to EBITDA (3.44b) ratio: 3.89 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.70 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (171.7m) change vs 12m ago -6.79% (target <= -2.0% for YES) |
| Gross Margin 33.78% (prev 33.42%; Δ 0.36pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 56.89% (prev 56.35%; Δ 0.55pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 3.26 (EBITDA TTM 3.44b / Interest Expense TTM 707.0m) >= 6 (WARN >= 3) |
Altman Z'' 1.04
| (A) -0.09 = (Total Current Assets 5.98b - Total Current Liabilities 8.51b) / Total Assets 28.73b |
| (B) 0.24 = Retained Earnings (Balance) 6.91b / Total Assets 28.73b |
| (C) 0.08 = EBIT TTM 2.31b / Avg Total Assets 27.95b |
| (D) 0.27 = Book Value of Equity 5.99b / Total Liabilities 22.44b |
| Total Rating: 1.04 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 65.43
| 1. Piotroski 6.50pt |
| 2. FCF Yield 5.01% |
| 3. FCF Margin 16.60% |
| 4. Debt/Equity 2.47 |
| 5. Debt/Ebitda 3.89 |
| 6. ROIC - WACC (= 1.78)% |
| 7. RoE 21.40% |
| 8. Rev. Trend 91.75% |
| 9. EPS Trend -23.54% |
What is the price of IQV shares?
Over the past week, the price has changed by +6.77%, over one month by +6.61%, over three months by +22.78% and over the past year by +15.08%.
Is IQV a buy, sell or hold?
- Strong Buy: 14
- Buy: 2
- Hold: 7
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the IQV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 247.5 | 6.8% |
| Analysts Target Price | 247.5 | 6.8% |
| ValueRay Target Price | 252.5 | 8.9% |
IQV Fundamental Data Overview November 26, 2025
P/E Trailing = 31.3405
P/E Forward = 17.4216
P/S = 2.4834
P/B = 6.3083
P/EG = 0.9677
Beta = 1.375
Revenue TTM = 15.90b USD
EBIT TTM = 2.31b USD
EBITDA TTM = 3.44b USD
Long Term Debt = 12.79b USD (from longTermDebt, last quarter)
Short Term Debt = 2.16b USD (from shortTermDebt, last quarter)
Debt = 15.19b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 13.38b USD (from netDebt column, last quarter)
Enterprise Value = 52.71b USD (39.50b + Debt 15.19b - CCE 1.97b)
Interest Coverage Ratio = 3.26 (Ebit TTM 2.31b / Interest Expense TTM 707.0m)
FCF Yield = 5.01% (FCF TTM 2.64b / Enterprise Value 52.71b)
FCF Margin = 16.60% (FCF TTM 2.64b / Revenue TTM 15.90b)
Net Margin = 8.07% (Net Income TTM 1.28b / Revenue TTM 15.90b)
Gross Margin = 33.78% ((Revenue TTM 15.90b - Cost of Revenue TTM 10.53b) / Revenue TTM)
Gross Margin QoQ = 33.49% (prev 32.94%)
Tobins Q-Ratio = 1.83 (Enterprise Value 52.71b / Total Assets 28.73b)
Interest Expense / Debt = 1.24% (Interest Expense 189.0m / Debt 15.19b)
Taxrate = 18.63% (76.0m / 408.0m)
NOPAT = 1.88b (EBIT 2.31b * (1 - 18.63%))
Current Ratio = 0.70 (Total Current Assets 5.98b / Total Current Liabilities 8.51b)
Debt / Equity = 2.47 (Debt 15.19b / totalStockholderEquity, last quarter 6.16b)
Debt / EBITDA = 3.89 (Net Debt 13.38b / EBITDA 3.44b)
Debt / FCF = 5.07 (Net Debt 13.38b / FCF TTM 2.64b)
Total Stockholder Equity = 6.00b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.47% (Net Income 1.28b / Total Assets 28.73b)
RoE = 21.40% (Net Income TTM 1.28b / Total Stockholder Equity 6.00b)
RoCE = 12.27% (EBIT 2.31b / Capital Employed (Equity 6.00b + L.T.Debt 12.79b))
RoIC = 9.07% (NOPAT 1.88b / Invested Capital 20.69b)
WACC = 7.29% (E(39.50b)/V(54.69b) * Re(9.70%) + D(15.19b)/V(54.69b) * Rd(1.24%) * (1-Tc(0.19)))
Discount Rate = 9.70% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -3.48%
[DCF Debug] Terminal Value 73.74% ; FCFE base≈2.37b ; Y1≈2.55b ; Y5≈3.15b
Fair Price DCF = 242.9 (DCF Value 41.37b / Shares Outstanding 170.3m; 5y FCF grow 8.85% → 3.0% )
EPS Correlation: -23.54 | EPS CAGR: 4.43% | SUE: 0.15 | # QB: 0
Revenue Correlation: 91.75 | Revenue CAGR: 3.25% | SUE: 0.69 | # QB: 0
Additional Sources for IQV Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle